The Radiosurgery Society (RSS), a non-profit medical society dedicated to advancing the science and clinical practice of radiosurgery, recently published a study using data from its RSSearch Patient Registry, a multi-institutional, observational registry established to standardize data collection from patients treated with stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT).
The study was titled “Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry’s experience,” and examined outcomes from 447 patients treated for lung metastases using SBRT at 30 academic and community cancer centers participating in the RSSearch Patient Registry.
The study found five year survival of 21.8 percent consistent with the survival benefit of local treatment such as surgery previously published for low volume metastatic disease (oligometastases). The study also found that patients with smaller metastases treated with higher doses of SBRT with a biological effective dose of at least 100Gy had the best local control. There was no difference in local control between different tumor types, however survival was improved for breast and head and neck cancer consistent with a longer natural history.
“The RSSearch Patient Registry is an important resource in expanding knowledge and understanding of SRS and SBRT treatment practices and outcomes,” said Joanne Davis, Ph.D., Executive Director, RSS. “Not only is this the sixth manuscript generated from RSSearch data, it is the third focused on SBRT for the treatment of lung tumors, providing clinicians with important clinical information on the use of SRS/SBRT to treat this highly prevalent and very deadly form of cancer.”
At Columbus CyberKnife, lung tumors are treated with SBRT using the CyberKnife® Robotic Radiosurgery System. CyberKnife is a painless, non-invasive outpatient cancer treatment with minimal to no side effects. During the CyberKnife treatment, hundreds of highly concentrated and incredibly precise beams of radiation are targeted directly to tumors and lesions in the lung. As the patient breathes during the CyberKnife treatment, the CyberKnife robotic arm moves with the rise and fall of his/her body – meaning that healthy tissue is protected from radiation and only the tumor is treated.
To learn more about treating lung tumors with CyberKnife technology, please click here.